Method of treating immune pathologies with low dose estrogen

Details Method of treating immune pathologies with low dose estrogen Method of treating immune pathologies with low dose estrogen

2008-05-13

2008-05-13

Ewoldt, G. R. (Department: 1644)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S198100

Reexamination Certificate

active

10275833

ABSTRACT:
The invention provides a method of ameliorating a Th1-mediated immune pathology in a mammal. The method is practiced by administering a low dose of estrogen to the mammal. Optionally, an immunotherapeutic agent can also be administered to the mammal. Also provided are kits containing a low dose of estrogen and an immunotherapeutic agent.

REFERENCES:
patent: 5194425 (1993-03-01), Sharma et al.
patent: 5223426 (1993-06-01), Skibbens et al.
patent: 5569585 (1996-10-01), Goodwin et al.
patent: 5612035 (1997-03-01), Howell et al.
patent: 5614192 (1997-03-01), Vandenbark
patent: 5776459 (1998-07-01), Vandenbark
patent: 5837246 (1998-11-01), Howell et al.
patent: 5856446 (1999-01-01), Weiner et al.
patent: 5858968 (1999-01-01), Weiner et al.
patent: 5869093 (1999-02-01), Weiner et al.
patent: 5939281 (1999-08-01), Lehmann et al.
patent: 5939400 (1999-08-01), Steinman et al.
patent: 6019971 (2000-02-01), Weiner et al.
patent: 6039947 (2000-03-01), Weiner et al.
patent: 6045796 (2000-04-01), Sriram et al.
patent: 6090387 (2000-07-01), Howell et al.
patent: 6113903 (2000-09-01), Albertini et al.
patent: 6159470 (2000-12-01), Howell et al.
patent: 6197926 (2001-03-01), Gaur
patent: 6207645 (2001-03-01), Howell et al.
patent: 6218132 (2001-04-01), Spack et al.
patent: 6221352 (2001-04-01), Howell et al.
patent: 6958327 (2005-10-01), Hillisch et al.
patent: 2002/0183299 (2002-12-01), Voskuhl
patent: 0 159 739 (1985-10-01), None
patent: WO 99/58977 (1999-11-01), None
patent: WO 94/25063 (1994-11-01), None
Carlsten et al., 1996, Infamm Res. vol. 45: 26-30.
Correale et al., 1998, J. Immunol. vol. 161: 3365-3374.
Zipp et al., 1998, Brain, vol. 121: 1395-1407.
Gilmore et al., 1997, J. Immunol. vol. 158: 446-451.
Martin et al., 2001, Nat. Immunol. vol. 2: 785-788.
Steinman et al., 2005, Trends in Immunology, vol. 26: 565-571.
Arden et al..Immunogenetics42:355-500 (1995).
Bebo et al..J. Immunol. 162:35 (1998).
Bebo et al..J. Neurosci. Res. 52:420-429 (1998).
Bourdette et al..Cell Immunol. 112:351 (1988).
Choi et al..Proc. Natl. Acad. Sci. USA 86:8941-8945 (1989).
Cochlovius et al..J. Immunol. 165:4731-4741 (2000).
Concannon et al..Proc. Natl. Acad. Sci. USA 83:6598-6602 (1986).
Correale et al.,J. Immunol. 161:3365-3374 (1998).
Dalton et al.,Science259:1739-1742 (1993).
Evavold et al.,Immunology Today14:602-609 (1993).
Fairchild,Euro. J. Immunogenet. 24:155-167 (1997).
Genevee et al.,Eur. J. Immunol. 22:1261-1269 (1992).
Goverman et al.,Cell72:551-560 (1993).
Hashim et al.,J. Immunol. 144:4621-4627 (1990).
Kimura et al.,Eur J. Immunol. 17:375-383 (1987).
Kumar et al.,J. Exp. Med. 178:909-916 (1993).
Offner et al.,J. Immunol. 161:2178-2186 (1998).
Robinson et al.,J. Immunol. 146:4392-4397 (1991).
Roselli et al.,Endocrine64:139 (1996).
Rovaris et al.J. Neurol. Sci. 186 Suppl. 1:S3-9 (2001).
Savoie et al.,Pac. Symp. Biocomput. 1999:182-189 (1999).
Sicotte et al..Ann. Neurol52:421-428 (2002).
Vaniene et al..J. Neurosci. Res. 45:475-486 (1996).
Jansson et al.,Journal of Neuroimmunology53:203-207 (1994).
Offner et al.,Journal of Clinical Investigation105(10): 1465-1472 (2000).
Brosterhaus et al., “Enrichment and detection of live antigen-specific CD4+ T cells based on cytokine secretion,”Eur. J. Immunol. 29:4053-4056, 1999.
Chou et al., “Immunity to TCR peptides in multiple sclerosis,”J. Immunol. 152:2520-2529, 1994.
Chou et al., “MHC-restriction, cytokine profile, and immunoregulatory effects of human T cells specific for TCR Vβ CDR2 peptides: comparison with myelin basic protein-specific T cells,”J. Neuroscience Res. 45:838-851, 1996.
Olsson et al., “Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-γ,”J. Clin. Invest. 86:981-985, 1990.
Thornton and Shevach, “CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production,”J. Experimental Medicine188 (2):287-296, 1998.
Vandenbark et al., “Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trail,”Nature Med. 2:1109-1115, 1996.
Vandenbark, “TCR Peptide Vaccination in Multiple Sclerosis: Boosting a Deficient Natural Regulatory Network that may Involve TCR- Specific CD4+CD25+ Treg Cells,”Current Drug Targets4:217-229, 2005.
Venken et al., “Secondary Progressive in Contrast to Relapsing-Remitting Multiple Sclerosis Patients Show a Normal CD4+CD25+ Regulatory T-Cell Function and FOXP3 Expression,”J. Neuroscience Research83:1432-1446, 2006.
Acha-Orbea et al., “Limited Heterogeneity of T Cell Receptors from Lymphocytes Mediating Autoimmune Encephalomyelitis Allows Specific Immune Intervention,”Cell56:263-273, Jul. 15, 1988.
Soldan et al., “Immune Modulation in Multiple Sclerosis Patients Treated with the Pregnancy Hormone Estriol,”J. Immunology171:6267-6274, 2003.
Van Epps, “Thomas Rivers and the EAE Model,”JEM202(1):4, Jul. 4, 2005.
English Translation of Japanese Patent Application No. JP101175854 dated Jun. 30, 1998, found at http://www4.jpdl.ncipi.go.jp/cgi-bin/tran, printed Sep. 14, 2006.

Affiliated with

Also associated with

Rating

Method of treating immune pathologies with low dose estrogen does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating immune pathologies with low dose estrogen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating immune pathologies with low dose estrogen will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3948284